- Vaccine Name: Intanza
- Target Pathogen: Influenza virus
- Target Disease: Influenza (flu)
- Product Name: Influenza Vaccine (Split Virion, Inactivated)
- Tradename: Intanza
- Manufacturer: Sanofi Pasteur Ltd.
- Vaccine Ontology ID: VO_0001248
- Type: Inactivated or "killed" vaccine
- Status: Licensed
- Location Licensed: Canada, European Union
- Host Species for Licensed Use: Human
- Antigen: Haemagglutinin (HA) of split influenza virus, inactivated, of each strain: A/California/7/2009 (H1N1)-like strain, A/Perth/16/2009 (H3N2)-like strain and B/Brisbane/60/2008 (Intanza Product Monograph).
- Allergen: Neomycin, formaldehyde, and ovalbumin (Intanza Product Monograph).
- Immunization Route: Intradermal injection (i.d.)
- Storage: Store at 2° to 8°C (35° to 46°F).
- Approved Age for Licensed Use: Ages 18 and older.
- Description: INTANZA™ [Influenza Vaccine (Split Virion, Inactivated)] is a sterile, colourless and opalescent suspension containing 3 strains of influenza virus cultivated on embryonated eggs, concentrated, purified by zonal centrifugation in a sucrose gradient, split by Triton® X-100, inactivated by formaldehyde, concentrated and then diluted in phosphate buffered saline solution. The type of viral antigens contained in INTANZA™ conform to the current requirements of the World Health Organization (WHO). The strains for the 2010 - 2011 season are: A/California/7/2009 (H1N1)-like strain, A/Perth/16/2009 (H3N2)-like strain and B/Brisbane/60/2008 (Intanza Product Monograph).
|
